ATX-202

Drug Profile

ATX-202

Alternative Names: ATX 202

Latest Information Update: 15 Jul 2015

Price : $50

At a glance

  • Originator Kythera Biopharmaceuticals
  • Class Peptides; Skin disorder therapies
  • Mechanism of Action Melanin stimulants; Melanocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Vitiligo

Most Recent Events

  • 21 Jul 2010 Phase-I clinical trials in Vitiligo in USA (Topical)
  • 16 Jun 2008 Preclinical trials in Vitiligo in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top